BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kloosterboer SM, de Winter BCM, Reichart CG, Kouijzer MEJ, de Kroon MMJ, van Daalen E, Ester WA, Rieken R, Dieleman GC, van Altena D, Bartelds B, van Schaik RHN, Nasserinejad K, Hillegers MHJ, van Gelder T, Dierckx B, Koch BCP. Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder. Br J Clin Pharmacol 2021;87:1069-81. [PMID: 32643213 DOI: 10.1111/bcp.14465] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Taurines R, Fekete S, Preuss-Wiedenhoff A, Warnke A, Wewetzer C, Plener P, Burger R, Gerlach M, Romanos M, Egberts KM. Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone. J Neural Transm (Vienna) 2022. [PMID: 35303169 DOI: 10.1007/s00702-022-02485-6] [Reference Citation Analysis]
2 Alsayouf HA, Talo H, Biddappa ML. Core Signs and Symptoms in Children with Autism Spectrum Disorder Improved after Starting Risperidone and Aripiprazole in Combination with Standard Supportive Therapies: A Large, Single-Center, Retrospective Case Series. Brain Sciences 2022;12:618. [DOI: 10.3390/brainsci12050618] [Reference Citation Analysis]
3 Egberts K, Fekete S, Häge A, Hiemke C, Scherf-Clavel M, Taurines R, Unterecker S, Gerlach M, Romanos M. [Therapeutic drug monitoring to optimize psychopharmacotherapy in children and adolescents - Update and guidelines for practice]. Z Kinder Jugendpsychiatr Psychother 2021;50:133-52. [PMID: 35274573 DOI: 10.1024/1422-4917/a000845] [Reference Citation Analysis]
4 Maruf AA, Stein K, Arnold PD, Aitchison KJ, Müller DJ, Bousman C. CYP2D6 and Antipsychotic Treatment Outcomes in Children and Youth: A Systematic Review. J Child Adolesc Psychopharmacol 2021;31:33-45. [PMID: 33074724 DOI: 10.1089/cap.2020.0093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Carthy E, Ross C, Murphy D. Psychotropic medication prescribing in people with autism spectrum disorders with and without psychiatric comorbidity. BJPsych advances. [DOI: 10.1192/bja.2021.32] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Guerra Valero Y, Dorofaeff T, Parker L, Coulthard MG, Sparkes L, Lipman J, Wallis SC, Roberts JA, Parker SL. Microsampling to support pharmacokinetic clinical studies in pediatrics. Pediatr Res 2021. [PMID: 34023854 DOI: 10.1038/s41390-021-01586-4] [Reference Citation Analysis]
7 Siafis S, Çıray O, Wu H, Schneider-Thoma J, Bighelli I, Krause M, Rodolico A, Ceraso A, Deste G, Huhn M, Fraguas D, San José Cáceres A, Mavridis D, Charman T, Murphy DG, Parellada M, Arango C, Leucht S. Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. Mol Autism 2022;13:10. [PMID: 35246237 DOI: 10.1186/s13229-022-00488-4] [Reference Citation Analysis]
8 Ludyga S, Pühse U, Gerber M, Mücke M. Muscle strength and executive function in children and adolescents with autism spectrum disorder. Autism Res 2021. [PMID: 34351051 DOI: 10.1002/aur.2587] [Reference Citation Analysis]